Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
Katodritou E, Terpos E, Symeonidis AS, Pouli A, Kelaidi C, Kyrtsonis MC, Kotsopoulou M, Delimpasi S, Christoforidou A, Giannakoulas N, Viniou NA, Stefanoudaki E, Hadjiaggelidou C, Christoulas D, Verrou E, Gastari V, Papadaki S, Polychronidou G, Papadopoulou A, Giannopoulou E, Kastritis E, Kouraklis A, Konstantinidou P, Anagnostopoulos A, Zervas K, Dimopoulos MA. Katodritou E, et al. Among authors: zervas k. Am J Hematol. 2014 Aug;89(8):803-8. doi: 10.1002/ajh.23745. Epub 2014 May 12. Am J Hematol. 2014. PMID: 24757085 Free article.
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.
Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Christoulas D, Pouli A, Michalis E, Verrou E, Anargyrou K, Tsionos K, Dimopoulos MA, Zervas K; Greek Myeloma Study Group. Terpos E, et al. Among authors: zervas k. Haematologica. 2009 Mar;94(3):372-9. doi: 10.3324/haematol.2008.000638. Haematologica. 2009. PMID: 19252175 Free PMC article. Clinical Trial.
No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years.
Kastritis E, Kyrtsonis MC, Hatjiharissi E, Symeonidis A, Michalis E, Repoussis P, Tsatalas K, Michael M, Sioni A, Kartasis Z, Stefanoudaki E, Voulgarelis M, Delimpasi S, Gavriatopoulou M, Koulieris E, Gika D, Vervesou E, Konstantopoulos K, Kokkini G, Zomas A, Roussou P, Anagnostopoulos N, Economopoulos T, Terpos E, Zervas K, Dimopoulos MA. Kastritis E, et al. Among authors: zervas k. Am J Hematol. 2011 Jun;86(6):479-83. doi: 10.1002/ajh.22027. Epub 2011 Apr 20. Am J Hematol. 2011. PMID: 21509798 Free article.
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.
Terpos E, Christoulas D, Katodritou E, Bratengeier C, Gkotzamanidou M, Michalis E, Delimpasi S, Pouli A, Meletis J, Kastritis E, Zervas K, Dimopoulos MA. Terpos E, et al. Among authors: zervas k. Int J Cancer. 2012 Sep 15;131(6):1466-71. doi: 10.1002/ijc.27342. Epub 2011 Dec 21. Int J Cancer. 2012. PMID: 22052418
Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era.
Dimopoulos MA, Kastritis E, Delimpasi S, Katodritou E, Hatzimichael E, Kyrtsonis MC, Repousis P, Tsirogianni M, Kartasis Z, Parcharidou A, Michael M, Michalis E, Tsatalas C, Stefanoudaki E, Hatjiharissi E, Gika D, Symeonidis A, Terpos E, Zervas K; Greek Myeloma Study Group. Dimopoulos MA, et al. Among authors: zervas k. Eur J Haematol. 2012 Jul;89(1):10-5. doi: 10.1111/j.1600-0609.2012.01784.x. Eur J Haematol. 2012. PMID: 22469521
The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group.
Terpos E, Christoulas D, Kastritis E, Katodritou E, Papatheodorou A, Pouli A, Kyrtsonis MC, Michalis E, Papanikolaou X, Gkotzamanidou M, Koulieris E, Gavriatopoulou M, Zervas K, Dimopoulos MA; Greek Myeloma Study Group. Terpos E, et al. Among authors: zervas k. Am J Hematol. 2014 Jan;89(1):34-40. doi: 10.1002/ajh.23577. Am J Hematol. 2014. PMID: 23983166 Free article.
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group.
Zervas K, Mihou D, Katodritou E, Pouli A, Mitsouli CH, Anagnostopoulos A, Delibasi S, Kyrtsonis MC, Anagnostopoulos N, Terpos E, Zikos P, Maniatis A, Dimopoulos MA; Greek Myeloma Study Group. Zervas K, et al. Ann Oncol. 2007 Aug;18(8):1369-75. doi: 10.1093/annonc/mdm178. Ann Oncol. 2007. PMID: 17693650 Free article. Clinical Trial.
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).
Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N, Michali E, Zomas A, Katodritou E, Gika D, Pouli A, Christoulas D, Roussou M, Kartasis Z, Economopoulos T, Dimopoulos MA. Kastritis E, et al. Among authors: zervas k. Leukemia. 2009 Jun;23(6):1152-7. doi: 10.1038/leu.2008.402. Epub 2009 Feb 19. Leukemia. 2009. PMID: 19225533
72 results